ESMO 2022 | Key trials in GU cancers from ESMO 2022

Camillo Guglielmo Porta, MD, University of Bari Aldo Moro, Bari, Italy, shares insight into key trials in genitourinary cancer presented at the European Society for Medical Oncology (ESMO) 2022 Congress, including the Phase III COSMIC-313 study (NCT03937219), which assessed the addition of cabozantinib to the current standard of care, nivolumab and ipilimumab, in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk. An improved progression-free survival (PFS) rate with the addition of cabozantinib was demonstrated, indicating this combination may potentially replace the standard of care. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.